Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Graciela M. Nogueras‐González et al.|Cancer Discovery|2018Cited by 570
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell LymphomaMark W. Clemens, Roberto N. Miranda, L. Jeffrey Medeiros et al.|Journal of Clinical Oncology|2015Cited by 418
The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Naval Daver, Sreyashi Basu et al.|Cancer|2018Cited by 339
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
Multidisciplinary Management of Orbital Metastasis and Survival OutcomesChristian El‐Hadad, Bita Esmaeli, Kirthi Koka et al.|Ophthalmic Plastic and Reconstructive Surgery|2021Cited by 13